Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.

@article{Katzenwadel2015AndrogenDO,
  title={Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.},
  author={Arndt Katzenwadel and Philipp Wolf},
  journal={Cancer letters},
  year={2015},
  volume={367 1},
  pages={12-7}
}
Androgen deprivation therapy (ADT) is considered as the standard therapy for men with de novo or recurrent metastatic prostate cancer. ADT commonly leads to initial biochemical and clinical responses. However, several months after the beginning of treatment, tumors become castration-resistant and virtually all patients show disease progression. At this stage, tumors are no longer curable and cancer treatment options are only palliative. In this review, we describe molecular alterations in tumor… CONTINUE READING

From This Paper

Topics from this paper.
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…